Kusajili – Clinical trials directory

Result of your search per sponsor: IPSEN Research and Development, BEAUFOUR IPSEN PHARMA

Woman and Man Max 99 years
IPSEN Research and Development, BEAUFOUR IPSEN PHARMA Update Il y a 4 ans

Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour The main objective is to assess the effect of lanreotide Autogel 120 mg administered every 28 days compared to placebo, on progression-free survival in patients with well or moderately differentiated ...

Country None
organs None
Specialty None

unknown

More information